Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 654-662

  Ferreri, Andrés J M ^a   Bruno Ventre, Marta ^a   Donadoni, Giovanni ^a   Ponzoni, Maurilio ^a,b   Citterio, Giovanni ^a   Foppoli, Marco ^a   Vignati, Alessandro ^a   Scarfò, Lydia ^a   Sassone, Marianna ^a   Govi, Silvia ^a   Caligaris Cappio, Federico ^a  

^a Unit of Lymphoid Malignancies   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Central nervous system prophylaxis; Diffuse large B cell lymphoma; Intrathecal chemotherapy; Liposomal cytarabine; Methotrexate

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG MEGADOSE; EXTRANODAL DISEASE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER CELL DAMAGE; LOW RISK PATIENT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MTHFR GENE; MULTIPLE CYCLE TREATMENT; NEUROPROTECTION; NEUTROPENIA; ORBIT DISEASE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROBABILITY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TESTIS DISEASE; TREATMENT DURATION; TREATMENT REFUSAL; VERY ELDERLY; ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RISK FACTOR; SECONDARY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VINCRISTINE;

EID: 84922929566     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13194     Document Type: Article

References (24)

1. Abramson, J.S., Hellmann, M., Barnes, J.A., Hammerman, P., Toomey, Ch., Takvorian, T., Muzikansky, A. & Hochberg, E.P. (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer, 116, 4283-4290.
2. Aviles, A., Jesus Nambo, M. & Neri, N. (2013) Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3, 258 patients in a single center. Medical Oncology, 30, 520-523.
3. Bjorkholm, M., Hagberg, H., Holte, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., Myhre, J., Pertovaara, H., Ost, A., Nilsson, B. & Osby, E. (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Annals of Oncology, 18, 1085-1089.
4. Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M., Schmitz, N. & German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the german high-grade non-hodgkin's lymphoma study group (DSHNHL). Annals of Oncology, 18, 149-157.
5. Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W. & Tubiana, M. (1971) Report of the committee on hodgkin's disease staging classification. Cancer Research, 31, 1860-1861.
6. Cheng, A.L., Yeh, K.H., Uen, W.C., Hung, R.L., Liu, M.Y. & Wang, C.H. (1998) Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer, 82, 1946-1951.
7. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored international working group. Journal of Clinical Oncology, 17, 1244-1252.
8. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V. & International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
9. Faganel Kotnik, B., Grabnar, I., Bohanec Grabar, P., Dolzan, V. & Jazbec, J. (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. European Journal of Clinical Pharmacology, 67, 993-1006.
10. Ferreri, A.J. (2011) How I treat primary CNS lymphoma. Blood, 118, 510-522.
11. Ferreri, A.J. (2014) Risk of CNS dissemination in extranodal lymphomas. The Lancet Oncology, 15, e159-e169.
12. Ferreri, A.J., Assanelli, A., Crocchiolo, R. & Ciceri, F. (2009) Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematological Oncology, 27, 61-70.
13. Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., Bordessoule, D., Recher, C., Blanc, M., Molina, T., Lederlin, P. & Coiffier, B. (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology, 15, 129-133.
14. Guirguis, H.R., Cheung, M.C., Mahrous, M., Piliotis, E., Berinstein, N., Imrie, K.R., Zhang, L. & Buckstein, R. (2012) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. British Journal of Haematology, 159, 39-49.
15. Haioun, C., Besson, C., Lepage, E., Thieblemont, C., Simon, D., Rose, C., Tilly, H., Sonet, A., Lederlin, P., Attal, M., Briere, J. & Reyes, F. (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. groupe d'etudes des lymphomes de l'adulte. Annals of Oncology, 11, 685-690.
16. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
17. Hollender, A., Kvaloy, S., Lote, K., Nome, O. & Holte, H. (2000) Prognostic factors in 140 adult patients with non-hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. European Journal of Cancer England, 36, 1762-1768.
18. Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M.L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L.M., Anderson, H., Jerkeman, M. & Eriksson, M. (2013) Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II nordic lymphoma group study. Annals of Oncology, 24, 1385-1392.
19. Krawczyk, K., Jurczak, W., Dlugosz-Danecka, M., Zauska-Giza, A., Dzietczenia, J., Wrobel, T. & Skotnicki, A.B. (2013) Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. Polskie Archiwum Medycyny Wewnetrznej, 123, 589-595.
20. McMillan, A., Ardeshna, K.M., Cwynarski, K., Lyttelton, M., McKay, P., Montoto, S. & British Committee for Standards in Haematology. (2013) Guideline on the prevention of secondary central nervous system lymphoma: british committee for standards in haematology. British Journal of Haematology, 163, 168-181.
21. Murawski, N., Held, G., Ziepert, M., Kempf, B., Viardot, A., Hanel, M., Witzens-Harig, M., Mahlberg, R., Rube, C., Fleckenstein, J., Zwick, C., Glass, B., Schmitz, N., Zeynalova, S. & Pfreundschuh, M. (2014) The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood, 124, 720-728.
22. Smith, J.R., Braziel, R.M., Paoletti, S., Lipp, M., Uguccioni, M. & Rosenbaum, J.T. (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood, 101, 815-821.
23. Stein, H., Warnke, R.A., Chang, W., Jaffe, E.S., Chang, J.K.C., Gatter, K.C. & Campo, E. (2008) Diffuse large B-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4 edn (eds by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 233-237. IARC, Lyon.
24. Wilson, W.H., Bromberg, J.E., Stetler-Stevenson, M., Steinberg, S.M., Martin-Martin, L., Muniz, C., Sancho, J.M., Caballero, M.D., Davidis, M.A., Brooimans, R.A., Sanchez-Gonzalez, B., Salar, A., Gonzalez-Barca, E., Ribera, J.M., Shovlin, M., Filie, A., Dunleavy, K., Mehrling, T., Spina, M. & Orfao, A. (2014) Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica, 99, 1228-1235.